162 related articles for article (PubMed ID: 35747809)
1. Transcriptional Regulation of ING5 and its Suppressive Effects on Gastric Cancer.
Zheng HC; Xue H; Wu X; Xu HL; Zhao EH; Cui ZG
Front Oncol; 2022; 12():918954. PubMed ID: 35747809
[TBL] [Abstract][Full Text] [Related]
2. The roles of ING5 in cancer: A tumor suppressor.
Zheng HC; Xue H; Jiang HM
Front Cell Dev Biol; 2022; 10():1012179. PubMed ID: 36425530
[TBL] [Abstract][Full Text] [Related]
3. ING5 suppresses proliferation, apoptosis, migration and invasion, and induces autophagy and differentiation of gastric cancer cells: a good marker for carcinogenesis and subsequent progression.
Gou WF; Shen DF; Yang XF; Zhao S; Liu YP; Sun HZ; Su RJ; Luo JS; Zheng HC
Oncotarget; 2015 Aug; 6(23):19552-79. PubMed ID: 25980581
[TBL] [Abstract][Full Text] [Related]
4. The roles of ING5 in gliomas: a good marker for tumorigenesis and a potential target for gene therapy.
Zhao S; Zhao ZJ; He HY; Wu JC; Ding XQ; Yang L; Jia N; Li ZJ; Zheng HC
Oncotarget; 2017 Aug; 8(34):56558-56568. PubMed ID: 28915612
[TBL] [Abstract][Full Text] [Related]
5. ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid.
Wu JC; Jiang HM; Yang XH; Zheng HC
Cancer Med; 2018 Sep; 7(9):4554-4569. PubMed ID: 30091530
[TBL] [Abstract][Full Text] [Related]
6. The altered expression of ING5 protein is involved in gastric carcinogenesis and subsequent progression.
Xing YN; Yang X; Xu XY; Zheng Y; Xu HM; Takano Y; Zheng HC
Hum Pathol; 2011 Jan; 42(1):25-35. PubMed ID: 21062663
[TBL] [Abstract][Full Text] [Related]
7. The down-regulated ING5 expression in lung cancer: a potential target of gene therapy.
Zhao S; Yang XF; Shen DF; Gao Y; Shi S; Wu JC; Liu HX; Sun HZ; Su RJ; Zheng HC
Oncotarget; 2016 Aug; 7(34):54596-54615. PubMed ID: 27409347
[TBL] [Abstract][Full Text] [Related]
8. ING5 suppresses breast cancer progression and is regulated by miR-24.
Cui S; Liao X; Ye C; Yin X; Liu M; Hong Y; Yu M; Liu Y; Liang H; Zhang CY; Chen X
Mol Cancer; 2017 May; 16(1):89. PubMed ID: 28490335
[TBL] [Abstract][Full Text] [Related]
9. The roles of ING5 expression in ovarian carcinogenesis and subsequent progression: a target of gene therapy.
Zheng HC; Zhao S; Song Y; Ding XQ
Oncotarget; 2017 Nov; 8(61):103449-103464. PubMed ID: 29262575
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
Wang ZT; Chen ZJ; Jiang GM; Wu YM; Liu T; Yi YM; Zeng J; Du J; Wang HS
Cell Signal; 2016 May; 28(5):506-515. PubMed ID: 26876786
[TBL] [Abstract][Full Text] [Related]
11. The nucleocytoplasmic translocation and up-regulation of ING5 protein in breast cancer: a potential target for gene therapy.
Ding XQ; Zhao S; Yang L; Zhao X; Zhao GF; Zhao SP; Li ZJ; Zheng HC
Oncotarget; 2017 Oct; 8(47):81953-81966. PubMed ID: 29137236
[TBL] [Abstract][Full Text] [Related]
12. The Roles of Beclin 1 Expression in Gastric Cancer: A Marker for Carcinogenesis, Aggressive Behaviors and Favorable Prognosis, and a Target of Gene Therapy.
Zheng HC; Zhao S; Xue H; Zhao EH; Jiang HM; Hao CL
Front Oncol; 2020; 10():613679. PubMed ID: 33425768
[TBL] [Abstract][Full Text] [Related]
13. ING5 is phosphorylated by CDK2 and controls cell proliferation independently of p53.
Linzen U; Lilischkis R; Pandithage R; Schilling B; Ullius A; Lüscher-Firzlaff J; Kremmer E; Lüscher B; Vervoorts J
PLoS One; 2015; 10(4):e0123736. PubMed ID: 25860957
[TBL] [Abstract][Full Text] [Related]
14. Decreased nuclear expression and increased cytoplasmic expression of ING5 may be linked to tumorigenesis and progression in human head and neck squamous cell carcinoma.
Li X; Nishida T; Noguchi A; Zheng Y; Takahashi H; Yang X; Masuda S; Takano Y
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1573-83. PubMed ID: 20182888
[TBL] [Abstract][Full Text] [Related]
15. ING5 inhibits cancer aggressiveness by inhibiting Akt and activating p53 in prostate cancer.
Barlak N; Capik O; Sanli F; Kilic A; Aytatli A; Yazici A; Ortucu S; Ittmann M; Karatas OF
Cell Biol Int; 2020 Jan; 44(1):242-252. PubMed ID: 31475765
[TBL] [Abstract][Full Text] [Related]
16. ING5 Inhibits Migration and Invasion of Esophageal Cancer Cells by Downregulating the IL-6/CXCL12 Signaling Pathway.
Wang Y; Tan J; Li J; Chen H; Wang W
Technol Cancer Res Treat; 2021; 20():15330338211039940. PubMed ID: 34520285
[TBL] [Abstract][Full Text] [Related]
17. PKNOX2 suppresses gastric cancer through the transcriptional activation of IGFBP5 and p53.
Zhang L; Li W; Cao L; Xu J; Qian Y; Chen H; Zhang Y; Kang W; Gou H; Wong CC; Yu J
Oncogene; 2019 Jun; 38(23):4590-4604. PubMed ID: 30745575
[TBL] [Abstract][Full Text] [Related]
18. ING5 inhibits lung cancer invasion and epithelial-mesenchymal transition by inhibiting the WNT/β-catenin pathway.
Liu XL; Meng J; Zhang XT; Liang XH; Zhang F; Zhao GR; Zhang T
Thorac Cancer; 2019 Apr; 10(4):848-855. PubMed ID: 30810286
[TBL] [Abstract][Full Text] [Related]
19. ING5 activity in self-renewal of glioblastoma stem cells via calcium and follicle stimulating hormone pathways.
Wang F; Wang AY; Chesnelong C; Yang Y; Nabbi A; Thalappilly S; Alekseev V; Riabowol K
Oncogene; 2018 Jan; 37(3):286-301. PubMed ID: 28925404
[TBL] [Abstract][Full Text] [Related]
20. BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy.
Zheng HC; Li J; Shen DF; Yang XF; Zhao S; Wu YZ; Takano Y; Sun HZ; Su RJ; Luo JS; Gou WF
Oncotarget; 2015 Aug; 6(23):19685-705. PubMed ID: 26050197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
